Systemic and local immunosuppression in pancreatic cancer patients

Clinical Cancer Research

Volumn 7, Issue 11 SUPPL., 2001, Pages

  Von Bernstorff, Wolfram ^a   Voss, Martina ^a   Freichel, Susanne ^a   Schmid, Andreas ^a   Vogel, Ilka ^a   Jöhnk, Claudia ^a   Henne Bruns, Doris ^a   Kremer, Bernd ^a   Kalthoff, Holger ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD3 ANTIGEN, ZETA CHAIN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; INTERLEUKIN 10; TGFB1 PROTEIN, HUMAN; TGFB2 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; BLOOD; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LYMPH NODE METASTASIS; LYMPHOCYTE; MALE; METABOLISM; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD3; ANTIGENS, CD4; ANTIGENS, CD8; CARCINOMA, PANCREATIC DUCTAL; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSION; IMMUNOTHERAPY; INTERLEUKIN-10; LYMPHATIC METASTASIS; LYMPHOCYTES; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

EID: 0035291879     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Janes, R. H., Jr., Niederhuber, J. E., Chmiel, J. S., Winchester, D. P., Ocwieja, K. C., Karnell, J. H., Clive, R. E., and Menck, H. R. National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer. Ann Surg., 223: 261-272, 1996.
2. Braakman, E., Goedegebuure, P. S., Vreugdenhil, R. J., Segal, D. M., Shaw, S., and Bolhuis, R. L. ICAM-melanoma cells are relatively resistant to CD3-mediated T-cell lysis. Int. J. Cancer. 46: 475-480, 1990.
3. Chen, L., Ashe, S., Brady, W. A., Hellstrom, I., Hellstrom, K. E., Ledbetter, J. A., McGowan, P., and Linsley, P. S. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 71: 1093-1102, 1992.
4. Chan, A. K., Goedegebuure, P. S., von Bernstorff, W., Carritte, A. L., Chung, M., Stewart, R. A., Montgomery, L., Spanjaard, R. A., McKenzie, A. B., and Eberlein, T. J. B7.1 costimulation increases T-cell proliferation and cytotoxicity via selective expansion of specific variable α and β genes of the T-cell receptor. Surgery, 127: 342-350, 2000.
5. von Bernstorff, W., Spanjaard, R. A., Chan, A. K., Lockhart, D. C., Sadanaga, N., Wood, I., Peiper, M., Goedegebuure, P. S., and Eberlein, T. J. Pancreatic cancer cells can evade immune surveillance via non-functional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery, 125: 73-84, 1999.
6. Ungefroren, H., Voss, M., Jansen, M., Roeder, C., Henne-Bruns, D., Kremer, B., and Kalthoff, H. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res.. 58: 1741-1749, 1998.
7. Voss, M., Wolff, B., Savitskaia, N., Ungefroren, H., Deppert, W., Schmiegel, W., Kalthoff, H., and Naumann, M. TGFβ-induced growth inhibition involves cell cycle inhibitor p21 and pRb independent from p15 expression. Int. J. Oncol., 14: 93-101, 1999.
8. Holland, G., and Zlotnik, A. Interleukin-10 and cancer. Cancer Investig., 11: 751-758, 1993.
9. Chan, A. K., Lockhart, D. C., von Bernstorff, W., Spanjaard, R. A., Joo, H. G., Eberlein, T. J., and Goedegebuure, P. S. Soluble MUC1 secreted by human epithelial cancer cells mediates immune suppression by blocking T-cell activation. Int. J. Cancer, 82: 721-726, 1999.
10. Botti, C., Seregni, E., Ferrari, L., Martinetti, A., and Bombardieri, E. Immunosuppressive factors: role in cancer development and progression. Int. J. Biol. Markers, 13: 51-69, 1998.
11. Massague, J., Cheifetz, S., Laiho, M., Ralph, D. A., Weis, F. M., and Zentella, A. Transforming growth factor-β. Cancer Surv., 12: 81-103, 1992.
12. Juhl, H., Stritzel, M., Wroblewski, A., Henne-Bruns, D., Kremer, B., Schmiegel, W., Neumaier, M., Wagener, C., Schreiber, H. W., and Kalthoff, H. Immunocytological detection of micrometastatic cells: comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients. Int. J. Cancer, 57: 330-335, 1994.
13. Vogel, I., Kruger, U., Marxsen, J., Soeth, E., Kalthoff, H., Henne-Bruns, D., Kremer, B., and Juhl, H. Disseminated tumor cells in pancreatic cancer patients detected by immunocytology: a new prognostic factor. Clin. Cancer Res., 5: 593-599, 1999.
14. Wegener, A. M., Letourneur, F., Hoeveler, A., Brocker, T., Luton, F., and Malissen, B. The T cell receptor/CD3 complex is composed of at least two autonomous transduction modules. Cell, 68: 83-95, 1992.
15. Rudd, C. E., Janssen, O., Cai, Y. C., da Silva, A. J., Raab, M., and Prasad, K. V. Two-step TCR ζ/CD3-CD4, and CD28 signaling in T cells, SH2/SH3 domains, protein-tyrosine and lipid kinases. Immunol. Today, 15: 225-234, 1994.
16. Soeth, E., Vogel, I., Roder, C., Juhl, H., Marxsen, J., Kruger, U., Henne-Bruns, D., Kremer, B., and Kalthoff, H. Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. Cancer Res., 57: 3106-3110, 1997.
17. Hammarstrom, S., Shively, J. E., Paxton, R. J., Beatty, B. G., Larsson, A., Ghosh, R., Bormer, O., Buchegger, F., Mach, J. P., Burtin, P., et al. Antigenic sites in carcinoembryonic antigen. Cancer Res., 49: 4852-4858, 1989.
18. Koprowski, H., Steplewski, Z., Mitchell, K., Herlyn, M., Herlyn, D., and Fuhrer, P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet., 5: 957-971, 1979.
19. Herlyn, M., Steplewski, Z., Herlyn, D., and Koprowski, H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc. Natl. Acad. Sci. USA, 76: 1438-1452, 1979.
20. Schmiegel, W. H., Kalthoff, H., Arndt, R., Gieseking, J., Greten, H., Kloppel, G., Kreiker, C., Ladak, A., Lampe, V., and Ulrich, S. Monoclonal antibody-defined human pancreatic cancer-associated antigens. Cancer Res., 45: 1402-1407, 1985.
21. De Vita, F., Orditura, M., Galizia, G., Romano, C., Infusino, S., Auriemma, A., Lieto, E., and Catalano, G. Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. Cancer (Phila.), 86: 1936-1943, 1999.
22. Chau, G. Y., Wu, C. W., Lui, W. Y., Chang, T. J., Kao, H. L., Wu, L. H., King, K. L., Loong, C. C., Hsia, C. Y., and Chi, C. W. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann. Surg., 231: 552-558, 2000.
23. Bellone, G., Turletti, A., Artusio, E., Mareschi, K., Carbone, A., Tibaudi, D., Robecchi, A., Emanuelli, G., and Rodeck, U. Tumor-associated transforming growth factor-β and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am. J. Pathol., 155: 537-547, 1999.
24. Kucharzik, T., Lugering, N., Winde, G., Domschke, W., and Stoll, R. Colon carcinoma cell lines stimulate monocytes and lamina propria mononuclear cells to produce IL-10. Clin. Exp. Immunol., 110: 296-302, 1997.
25. Wunderlich, H., Steiner, T., Kosmehl, H., Junker, U., Reinhold, D., Reichelt, O., Zermann, D. H., and Schubert, J. Increased transforming growth factor β1 plasma level in patients with renal cell carcinoma: a tumor-specific marker? Urol. Int., 60: 205-207, 1998.
26. Ivanovic, V., Melman, A., Davis-Joseph, B., Valcic, M., and Geliebter, J. Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer. Nat. Med., 1: 282-284, 1995.
27. Shirai, Y., Kawata, S., Ito, N., Tamura, S., Takaishi, K., Kiso, S., Tsushima, H., and Matsuzawa, Y. Elevated levels of plasma transforming growth factor-β in patients with hepatocellular carcinoma. Jpn. J. Cancer Res., 83: 676-679, 1992.
28. Shim, K. S., Kim, K. H., Park, B. W., Yi, S. Y., Choi, J. H., Han, W. S., and Park, E. B. Increased serum levels of transforming growth factor-α in patients with colorectal cancer. Dis. Colon Rectum, 41: 219-224, 1998.
29. Nakamura, M., Katano, M., Kuwahara, A., Fujimoto, K., Miyazaki, K., Morisaki, T., and Mori, M. Transforming growth factor β1 (TGF-β1) is a preoperative prognostic indicator in advanced gastric carcinoma. Br. J. Cancer, 78: 1373-1378, 1998.
30. Takanami, I., Tanaka, F., Hashizume, T., and Kodaira, S. Roles of the transforming growth factor β1 and its type I and II receptors in the development of a pulmonary adenocarcinoma: results of an immunohistochemical study. J. Surg. Oncol., 64: 262-267, 1997.
31. Xu, J., Menezes, J., Prasad, U., and Ahmad, A. Elevated serum levels of transforming growth factor β1 in Epstein-Barr virus-associated nasopharyngeal carcinoma patients. Int. J. Cancer, 84: 396-399, 1999.
32. Friess, H., Lu, Z., Riesle, E., Uhl, W., Brundler, A. M., Horvath, L., Gold, L. I., Korc, M., and Buchler, M. W. Enhanced expression of TGF-βs and their receptors in human acute pancreatitis. Ann. Surg., 227: 95-104, 1998.
33. Hamerlinck, F. F. Neopterin: a review. Exp. Dermatol., 8: 167-176, 1999.
34. Birk, D., Gansauge, F., Gansauge, S., Schwarz, A., and Beger, H. G. Levels of serum neopterin are increased in pancreatic cancer patients and correlate with the prognosis. Eur. J. Med. Res., 4: 156-160, 1999.
35. Naito, Y., Saito, K., Shiiba, K., Ohuchi, A., Saigenji, K., Nagura, H., and Ohtani, H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res., 58: 3491-3494, 1998.
36. Poznansky, M. C., Olszak, I. T., Foxall, R., Evans, R. H., Luster, A. D., and Scadden, D. T. Active movement of T cells away from a chemokine. Nat. Med., 6: 543-548, 2000.
37. Gastman, B. R., Johnson, D. E., Whiteside, T. L., and Rabinowich, H. Caspase-mediated degradation of T-cell receptor ζ-chain. Cancer Res., 59: 1422-1427, 1999.
38. Mizoguchi, H., O'Shea, J. J., Longo, D. L., Loeffler, C. M., McVicar, D. W., and Ochoa, A. C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice [see comments]. Science (Washington DC), 258: 1795-1798, 1992.
39. Nakagomi, H., Petersson, M., Magnusson, I., Juhlin, C., Matsuda, M., Mellstedt, H., Taupin, J. L., Vivier, E., Anderson, P., and Kiessling, R. Decreased expression of the signal-transducing ζ chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res., 53: 5610-5612, 1993.
40. Renner, C., Ohnesorge, S., Held, G., Bauer, S., Jung, W., Pfitzenmeier, J. P., and Pfreundschuh, M. T cells from patients with Hodgkin's disease have a defective T-cell receptor ζ chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood, 88: 236-241, 1996.
41. Kono, K., Ressing, M. E., Brandt, R. M., Melief, C. J., Potkul, R. K., Andersson, B., Petersson, M., Kast, W. M., and Kiessling, R. Decreased expression of signal-transducing ζ chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin. Cancer Res.. 2: 1825-1828, 1996.
42. Rabinowich, H., Reichert, T. E., Kashii, Y., Gastman, B. R., Bell, M. C., and Whiteside, T. L. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J. Clin. Investig., 101: 2579-2588, 1998.
43. Aoe, T., Okamoto, Y., and Saito, T. Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J. Exp. Med., 181: 1881-1886, 1995.
44. Kono, K., Salazar-Onfray, F., Petersson, M., Hansson, J., Masucci, G., Wasserman, K., Nakazawa, T., Anderson, P., and Kiessling, R. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing ζ molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity. Eur. J. Immunol., 26: 1308-1313, 1996.
45. Otsuji, M., Kimura, Y., Aoe, T., Okamoto, Y., and Saito, T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 ζ chain of T-cell receptor complex and antigen-specific T-cell responses. Proc. Natl. Acad. Sci. USA, 93: 13119-13124, 1996.
46. Cardi, G., Heaney, J. A., Schned, A. R., Phillips, D. M., Branda, M. T., and Ernstoff, M. S. T-cell receptor ζ-chain expression on tumor-infiltrating lymphocytes from renal cell carcinoma [published erratum appears in Cancer Res., 57: 4973, 1997]. Cancer Res., 57: 3517-3519, 1997.
47. Deakin, A. M., Singh, K., Crowe, J. S., Ellis, J. H., Dalgleish, A., Leicester, R. J., Finlayson, C. J., Miles, W. F., and Life, P. F. A lack of evidence for down-modulation of CD3 ζ expression in colorectal carcinoma and pregnancy using multiple detection methods. Clin. Exp. Immunol., 118: 197-204, 1999.
48. Horiguchi, S., Petersson, M., Nakazawa, T., Kanda, M., Zea, A. H., Ochoa, A. C., and Kiessling, R. Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. Cancer Res., 59; 2950-2956, 1999.